# Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B

> **NCT02234310** · PHASE3 · COMPLETED · sponsor: **Bioverativ, a Sanofi company** · enrollment: 33 (actual)

## Conditions studied

- Hemophilia B

## Interventions

- **BIOLOGICAL:** rFIXFc

## Key facts

- **NCT ID:** NCT02234310
- **Lead sponsor:** Bioverativ, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11-13
- **Primary completion:** 2019-08-20
- **Final completion:** 2019-08-20
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2022-03-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02234310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02234310, "Study to Determine the Safety and Efficacy of rFIXFc in Previously Untreated Males With Severe Hemophilia B". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02234310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*